Key result
Only ~35% of cardiovascular HRQoL instruments demonstrate sufficient content validity, and all show inadequate development.
Why the study?
Cardiovascular disease-specific health-related quality-of-life instruments are commonly used to measure patient-reported outcomes, but their content validity needed systematic identification and assessment.
Systematic Review (n=69)
The quality of development and content validity varies significantly among existing CVD-specific HRQoL instruments, highlighting the need for careful selection in clinical studies.
Answers are grounded in this paper and cite their sources.
Clinicians should select CVD HRQoL instruments with caution; review challenges reliance on most existing tools and extends need for better development.
OBJECTIVES: Health-related quality-of-life (HRQoL) instruments for cardiovascular diseases (CVD) have been commonly used to measure important patient-reported outcomes (PROs) in clinical trials and practices. This study aimed at systematically identifying and assessing the content validity of CVD-specific HRQoL instruments in clinical studies. METHODS: The research team searched Cumulative Index to Nursing and Allied Health Literature, Embase, and PubMed from inception to January 20, 2022. The research team included studies that reported the development and content validity for CVD-specific instruments. Two reviewers independently assessed the methodological quality using the Consensus-based Standards for the Selection of Health Measurement Instruments methods on evaluating content validity of PROs. Content analysis was used to categorize the items included in the instruments. RESULTS: The research team found 69 studies reporting the content validity of 40 instruments specifically developed for CVD. Fourteen (35.0%) were rated "sufficient" with very low to moderate quality of evidence. For PRO development, all instruments were rated "doubtful" or "inadequate." Twenty-eight (70.0%) instruments cover the core concepts of HRQoL. CONCLUSIONS: The quality of development and content validity vary among existing CVD-specific instruments. The evidence on the content validity should be considered when choosing a HRQoL instrument in CVD clinical studies and health economic evaluations.
No takes yet. Share an insight, caveat, or question.
Li et al. (2024) conducted a systematic review in Cardiovascular diseases (CVD) (n=69). CVD-specific health-related quality-of-life (HRQoL) instruments was evaluated on Content validity and methodological quality. Cardiovascular disease-specific HRQoL instruments showed variable quality, with only 14 of 40 rated as having sufficient content validity and all rated inadequate for development.
Synapse has enriched 10 related papers. Consider them for comparative context: